Business UpdateJul 6, 2026, 07:01 AM
Veraxa Biotech Prioritizes BiTAC Pipeline, Aims for 2028 IND
AI Summary
Veraxa Biotech AG provided a company and pipeline update, highlighting substantial progress in the first half of 2026. The company is prioritizing its novel BiTAC technology, expecting it to be the main value driver, and plans to channel the majority of its investments into the BiTAC portfolio. A key goal is to have the first BiTAC-TCE candidate, VXA-102, IND/CTA-ready by early 2028. To fund this growth, Veraxa intends to monetize selected non-BiTAC pipeline assets, including VXA-901 and a HER2-targeting ADC program, which are currently available for partnering.
Key Highlights
- Veraxa Biotech made substantial progress in its pipeline and partnering strategy in H1 2026.
- BiTAC molecules are expected to be the main value drivers, with investments channeled into this portfolio.
- The company aims to have its first BiTAC-TCE candidate, VXA-102, IND/CTA-ready by early 2028.
- Selected non-BiTAC pipeline assets will be monetized to finance the growth of the BiTAC portfolio.
- The current pipeline includes four BiTAC-based T cell engager programs for solid tumors.
- VXA-901 (FLT3-targeting antibody) and a HER2-targeting ADC program are available for partnering.
- Positive feedback was received from the recent BIO International Partnering Conference and other events.
Price Impact
More from VRXA